Literature DB >> 24288268

Human α1β3γ2L gamma-aminobutyric acid type A receptors: High-level production and purification in a functional state.

Zuzana Dostalova1, Xiaojuan Zhou, Aiping Liu, Xi Zhang, Yinghui Zhang, Rooma Desai, Stuart A Forman, Keith W Miller.   

Abstract

Gamma-aminobutyric acid type A receptors (GABA(A)Rs) are the most important inhibitory chloride ion channels in the central nervous system and are major targets for a wide variety of drugs. The subunit compositions of GABA(A)Rs determine their function and pharmacological profile. GABAA Rs are heteropentamers of subunits, and (α1)2 (β3)2 (γ2L)1 is a common subtype. Biochemical and biophysical studies of GABA(A)Rs require larger quantities of receptors of defined subunit composition than are currently available. We previously reported high-level production of active human α1β3 GABA(A)R using tetracycline-inducible stable HEK293 cells. Here we extend the strategy to receptors containing three different subunits. We constructed a stable tetracycline-inducible HEK293-TetR cell line expressing human (N)-FLAG-α1β3γ2L-(C)-(GGS)3 GK-1D4 GABA(A)R. These cells achieved expression levels of 70-90 pmol [(3)H]muscimol binding sites/15-cm plate at a specific activity of 15-30 pmol/mg of membrane protein. Incorporation of the γ2 subunit was confirmed by the ratio of [(3)H]flunitrazepam to [(3)H]muscimol binding sites and sensitivity of GABA-induced currents to benzodiazepines and zinc. The α1β3γ2L GABA(A)Rs were solubilized in dodecyl-D-maltoside, purified by anti-FLAG affinity chromatography and reconstituted in CHAPS/asolectin at an overall yield of ∼ 30%. Typical purifications yielded 1.0-1.5 nmoles of [(3)H]muscimol binding sites/60 plates. Receptors with similar properties could be purified by 1D4 affinity chromatography with lower overall yield. The composition of the purified, reconstituted receptors was confirmed by ligand binding, Western blot, and proteomics. Allosteric interactions between etomidate and [(3)H]muscimol binding were maintained in the purified state.
© 2013 The Protein Society.

Entities:  

Keywords:  HEK293 TetR cells; human α1β3γ2 GABAAR; purification; reconstitution

Mesh:

Substances:

Year:  2013        PMID: 24288268      PMCID: PMC3926741          DOI: 10.1002/pro.2401

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  35 in total

1.  Molecular characterization of Vibrio parahaemolyticus vSGLT: a model for sodium-coupled sugar cotransporters.

Authors:  E Turk; O Kim; J le Coutre; J P Whitelegge; S Eskandari; J T Lam; M Kreman; G Zampighi; K F Faull; E M Wright
Journal:  J Biol Chem       Date:  2000-08-18       Impact factor: 5.157

2.  Convulsant/barbiturate activity on the soluble gamma-aminobutyric acid-benzodiazepine receptor complex.

Authors:  R G King; M Nielsen; G B Stauber; R W Olsen
Journal:  Eur J Biochem       Date:  1987-12-15

3.  The gamma 3-subunit of the GABAA-receptor confers sensitivity to benzodiazepine receptor ligands.

Authors:  F Knoflach; T Rhyner; M Villa; S Kellenberger; U Drescher; P Malherbe; E Sigel; H Möhler
Journal:  FEBS Lett       Date:  1991-11-18       Impact factor: 4.124

Review 4.  Insights into the structure and pharmacology of GABA(A) receptors.

Authors:  Chris R J Carter; Janna L Kozuska; Susan M J Dunn
Journal:  Future Med Chem       Date:  2010-05       Impact factor: 3.808

5.  Characterization of a mouse serotonin 5-HT3 receptor purified from mammalian cells.

Authors:  R Hovius; A P Tairi; H Blasey; A Bernard; K Lundström; H Vogel
Journal:  J Neurochem       Date:  1998-02       Impact factor: 5.372

6.  The synthesis and high-level expression of a beta2-adrenergic receptor gene in a tetracycline-inducible stable mammalian cell line.

Authors:  Prashen Chelikani; Philip J Reeves; Uttam L Rajbhandary; H Gobind Khorana
Journal:  Protein Sci       Date:  2006-06       Impact factor: 6.725

7.  Mapping general anesthetic binding site(s) in human α1β3 γ-aminobutyric acid type A receptors with [³H]TDBzl-etomidate, a photoreactive etomidate analogue.

Authors:  David C Chiara; Zuzana Dostalova; Selwyn S Jayakar; Xiaojuan Zhou; Keith W Miller; Jonathan B Cohen
Journal:  Biochemistry       Date:  2012-01-23       Impact factor: 3.162

8.  Interaction of allosteric ligands with GABAA receptors containing one, two, or three different subunits.

Authors:  J Zezula; A Slany; W Sieghart
Journal:  Eur J Pharmacol       Date:  1996-04-22       Impact factor: 4.432

9.  Liposome solubilization and membrane protein reconstitution using Chaps and Chapso.

Authors:  J Cladera; J L Rigaud; J Villaverde; M Duñach
Journal:  Eur J Biochem       Date:  1997-02-01

10.  On high- and low-affinity agonist sites in GABAA receptors.

Authors:  Roland Baur; Erwin Sigel
Journal:  J Neurochem       Date:  2003-10       Impact factor: 5.372

View more
  21 in total

1.  Atomistic insights into human Cys-loop receptors by solution NMR.

Authors:  David D Mowrey; Monica N Kinde; Yan Xu; Pei Tang
Journal:  Biochim Biophys Acta       Date:  2014-03-28

2.  Dodecyl maltopyranoside enabled purification of active human GABA type A receptors for deep and direct proteomic sequencing.

Authors:  Xi Zhang; Keith W Miller
Journal:  Mol Cell Proteomics       Date:  2014-12-03       Impact factor: 5.911

3.  Synthesis and pharmacological evaluation of neurosteroid photoaffinity ligands.

Authors:  Pavel Y Savechenkov; David C Chiara; Rooma Desai; Alexander T Stern; Xiaojuan Zhou; Alexis M Ziemba; Andrea L Szabo; Yinghui Zhang; Jonathan B Cohen; Stuart A Forman; Keith W Miller; Karol S Bruzik
Journal:  Eur J Med Chem       Date:  2017-04-21       Impact factor: 6.514

4.  Cryo-electron microscopy reveals informative details of GABAA receptor structural pharmacology: implications for drug discovery.

Authors:  Richard W Olsen; A Kerstin Lindemeyer; Martin Wallner; Xiaorun Li; Kevin W Huynh; Z Hong Zhou
Journal:  Ann Transl Med       Date:  2019-07

5.  Contrasting actions of a convulsant barbiturate and its anticonvulsant enantiomer on the α1 β3 γ2L GABAA receptor account for their in vivo effects.

Authors:  Rooma Desai; Pavel Y Savechenkov; Dorota Zolkowska; Ri Le Ge; Michael A Rogawski; Karol S Bruzik; Stuart A Forman; Douglas E Raines; Keith W Miller
Journal:  J Physiol       Date:  2015-11-15       Impact factor: 5.182

6.  Identification of binding sites contributing to volatile anesthetic effects on GABA type A receptors.

Authors:  Kellie A Woll; Xiaojuan Zhou; Natarajan V Bhanu; Benjamin A Garcia; Manuel Covarrubias; Keith W Miller; Roderic G Eckenhoff
Journal:  FASEB J       Date:  2018-03-05       Impact factor: 5.191

7.  Inhibitable photolabeling by neurosteroid diazirine analog in the β3-Subunit of human hetereopentameric type A GABA receptors.

Authors:  Bo Wu; Selwyn S Jayakar; Xiaojuan Zhou; Katherine Titterton; David C Chiara; Andrea L Szabo; Pavel Y Savechenkov; Daniel E Kent; Jonathan B Cohen; Stuart A Forman; Keith W Miller; Karol S Bruzik
Journal:  Eur J Med Chem       Date:  2018-11-19       Impact factor: 6.514

8.  A potent photoreactive general anesthetic with novel binding site selectivity for GABAA receptors.

Authors:  Abdelrahman R Shalabi; Zhiyi Yu; Xiaojuan Zhou; Youssef Jounaidi; Hanwen Chen; Jiajia Dai; Daniel E Kent; Hua-Jun Feng; Stuart A Forman; Jonathan B Cohen; Karol S Bruzik; Keith W Miller
Journal:  Eur J Med Chem       Date:  2020-03-23       Impact factor: 6.514

9.  General Anesthetic Binding Sites in Human α4β3δ γ-Aminobutyric Acid Type A Receptors (GABAARs).

Authors:  David C Chiara; Youssef Jounaidi; Xiaojuan Zhou; Pavel Y Savechenkov; Karol S Bruzik; Keith W Miller; Jonathan B Cohen
Journal:  J Biol Chem       Date:  2016-11-07       Impact factor: 5.157

10.  Positive and Negative Allosteric Modulation of an α1β3γ2 γ-Aminobutyric Acid Type A (GABAA) Receptor by Binding to a Site in the Transmembrane Domain at the γ+-β- Interface.

Authors:  Selwyn S Jayakar; Xiaojuan Zhou; Pavel Y Savechenkov; David C Chiara; Rooma Desai; Karol S Bruzik; Keith W Miller; Jonathan B Cohen
Journal:  J Biol Chem       Date:  2015-07-30       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.